Pain News and Research

Latest Pain News and Research

Common pain relievers could cause hypertension

Diseases such as kidney failure and endocrine tumors are among the suspects causing high blood pressure - but could the common pain relievers in your medicine cabinet be the culprit? According to Prof. Ehud Grossman of Tel Aviv University's Sackler Faculty of Medicine and the Sheba Medical Center, many common over-the-counter and prescription medications are underlying causes of hypertension, which is a major risk factor for stroke, heart attack, and aneurisms.

21 Mar 2012

IDSA releases new rhinosinusitis guidelines

The vast majority of sinus infections are caused by viruses and should not be treated with antibiotics, suggest new guidelines released by the Infectious Diseases Society of America.

21 Mar 2012

Indian patent court licenses generic copy of Bayer’s blockbuster anticancer drug

Last week an Indian patent court shocked the $600 billion global pharmaceutical business by ordering Bayer, the German health care giant, to allow a tiny Indian generic drug company to sell cheap copies of the blockbuster cancer drug Nexavar – even though everyone agrees that the drug is protected by a patent. Instead, the court decided that Bayer had an obligation to make Nexavar available to people in India who needed it.

20 Mar 2012

Acelrx fourth quarter net loss increases to $6.4 million

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today reported financial results for the fourth quarter and year ended December 31, 2011.

20 Mar 2012

Ampio receives U.S. patent allowance for lead drug Ampion

Ampio Pharmaceuticals, Inc., a biopharmaceutical company conducting clinical trials on its three lead drugs, licensing distribution of these drugs and engaged in further drug development, today announced that it has received notice of allowance from the US Patent Office of an additional patent that complements and expands its anti inflammatory patent portfolio for its lead drug Ampion.

20 Mar 2012

Pediatricians' unconscious racial bias may affect pain medication decisions

Pediatricians who show an unconscious preference for European Americans tend to prescribe better pain-management for white patients than they do for African-American patients, new University of Washington research shows.

20 Mar 2012

Novartis' Arcapta Neohaler now available in the U.S. for COPD treatment

Novartis Pharmaceuticals Corporation today announced that once-daily Arcapta Neohaler (indacaterol inhalation powder) 75 mcg is now available in the US and in pharmacies nationwide.

20 Mar 2012

RBC Life Sciences 2011 consolidated net sales increases to $28.4 million

RBC Life Sciences, Inc., a provider of proprietary nutritional supplements, and wound care and pain management products, today reported consolidated net sales of $28.4 million for the year ended December 31, 2011, a 1% increase over 2010 consolidated net sales of $28.2 million.

19 Mar 2012

NIH awards Avaxia $1.5M Phase II SBIR grant to develop antibody therapeutic for IBD

Avaxia Biologics, Inc., a privately-held biotech company using its proprietary platform technology to develop orally-active antibody therapeutics for the treatment of gastrointestinal diseases, is proud to announce that it has received a second round of funding from the National Institutes of Health for its work in inflammatory bowel disease.

19 Mar 2012

Merz launches new, once daily Mederma Advanced Scar Gel

Mederma, the #1 doctor-and pharmacist-recommended brand for scars for over a decade, announced today the introduction of Mederma Advanced Scar Gel, which reduces the overall appearance of scars caused by injury, acne, surgery or burns with just one daily application. Mederma Advanced Scar Gel contains Cepalin, the same proprietary botanical extract derived from onions used in all Mederma® scar products and stretch marks therapy.

19 Mar 2012

QRxPharma, Actavis enter License and Option Agreement

QRxPharma Limited announced today execution of its License and Option Agreement with Actavis, Inc. which finalised the legal terms and conditions to commercialise MoxDuo IR in the US acute pain marketplace. The LOA completion follows a 20 December 2011 signing of a binding Letter of Intent secured by a US$6 million non-refundable upfront signing fee to QRxPharma.

19 Mar 2012

Convergence initiates CNV1014802 Phase II study in trigeminal neuralgia

Convergence Pharmaceuticals Limited, the company focused on the development of novel and high value analgesic medicines, today announced that the Phase II proof of concept study for CNV1014802 for the treatment of pain associated with trigeminal neuralgia (TN) has started.

19 Mar 2012

Lilly Oncology, NCCS to launch 2012 art competition and exhibition

Get your canvases, paintbrushes and cameras ready -- the subject is cancer and you are the storyteller. Lilly Oncology and the National Coalition for Cancer Survivorship (NCCS) today announced the launch of the 2012 Lilly Oncology On Canvas: Expressions of a Cancer Journey Art Competition and Exhibition.

17 Mar 2012

Study identifies primary care skills and competencies in opioid risk management

Primary care physicians are faced with treating a large proportion of chronic pain patients, but many do not often have specific training in the assessment and management of chronic pain, including the use of opioid medications for chronic pain management.

17 Mar 2012

The northeastern U.S. should prepare for a surge in Lyme disease this spring

The northeastern U.S. should prepare for a surge in Lyme disease this spring. And we can blame fluctuations in acorns and mouse populations, not the mild winter. So reports Dr. Richard S. Ostfeld, a disease ecologist at the Cary Institute of Ecosystem Studies in Millbrook, NY.

17 Mar 2012

$Enrollment commences in MORE Registry for DBS in patients with refractory epilepsy$

Enrollment commences in MORE Registry for DBS in patients with refractory epilepsy

Medtronic, Inc. today announced that a patient from Kempenhaeghe-Heeze (The Netherlands) is the first patient to be enrolled into the MORE (MedtrOnic Registry for Epilepsy) Registry which is designed to look at the long-term efficacy, quality of life impact and safety of deep brain stimulation (DBS) in patients with refractory epilepsy.

From Medtronic 17 Mar 2012

Results from AspenBio Pharma's AppyScore trial on appendicitis to be presented at SAEM meeting

The results from AspenBio Pharma's 503-patient pilot study of AppyScore will be presented from the podium the upcoming West Region meeting of the Society for Academic Emergency Medicine (SAEM) being held in Las Vegas, March 16-17.

17 Mar 2012

Harrington HealthCare introduces Strengthening Our Future campaign

Harrington HealthCare System today formally launched a fundraising campaign to rebuild the Emergency Department at its Webster campus, Harrington HealthCare at Hubbard. The $8.8 million Strengthening Our Future campaign will enable Harrington HealthCare at Hubbard to continue to deliver the highest quality care to its patients.

17 Mar 2012

SK Biopharmaceuticals initiates YKP10811 phase 2 trial in chronic constipation

SK Biopharmaceuticals, a South Korean pharmaceutical company, announced today that the first patient was dosed in a phase 2 clinical trial in the US for patients suffering with chronic constipation using their new chemical entity YKP10811.

17 Mar 2012

NEJM publishes results from Teva's laquinimod Phase III study on RRMS

Teva Pharmaceutical Industries Ltd. and Active Biotech today announced the publication of results from the laquinimod Phase III ALLEGRO study in the March 15 issue of The New England Journal of Medicine.

16 Mar 2012